menu
    • menu
    [{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"OrbiMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Private Placement","leadProduct":"Etigilimab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Mereo BioPharma Group \/ OrbiMed","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ OrbiMed"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT","graph1":"Oncology","graph2":"IND Enabling","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Etigilimab","moa":"TIGIT protein","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mereo BioPharma Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mereo BioPharma Group \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Etigilimab

    Menu

    Etigilimab

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etigilimab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Ph...

                            Details : The multicenter ACTIVATE study is designed to evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics of MPH-313 (etigilimab), Mereo’s proprietary anti-TIGIT antibody, in combination with a PD-1 inhibitor, nivolumab, with dosing every two...

                            Brand Name : MPH-313

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 12, 2022

                            Lead Product(s) : Etigilimab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etigilimab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022...

                            Details : Treatment of MPH-313 (etigilimab) in combination with nivolumab has shown preliminary efficacy across multiple tumor types with 2 complete responses, 4 partial responses, and 10 stable disease for an ORR of 15.8% and DCR of 42.1% in heavily pre-treated.

                            Brand Name : MPH-313

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 02, 2022

                            Lead Product(s) : Etigilimab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etigilimab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster a...

                            Details : The combination of MPH-313 (etigilimab) and nivolumab has been safe and well tolerated, with an overall response rate (ORR) of 11% and disease control rate (DCR) of 44% with no new safety signals observed to-date.

                            Brand Name : MPH-313

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 26, 2022

                            Lead Product(s) : Etigilimab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etigilimab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mereo Reports Interim Data from ACTIVATE Phase 1b/2 Study of Etigilimab

                            Details : Company promising efficacy, safety, and biomarker data from ACTIVATE aims to enroll approximately 125 patients across seven parallel cohorts of anti-TIGIT antibody MPH-313(etigilimab) in combination with nivolumab for recurrent advanced metastatic solid ...

                            Brand Name : MPH-313

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 30, 2021

                            Lead Product(s) : Etigilimab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etigilimab,Anti-PD-1 therapy

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)

                            Details : Mereo is on track to initiate the Phase 1b/2 basket study in the fourth quarter of 2020. The study will evaluate etigilimab in combination with an anti-PD-1 initially in 100 patients with a defined series of tumor types, including biomarker enriched and ...

                            Brand Name : MPH-313

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 19, 2020

                            Lead Product(s) : Etigilimab,Anti-PD-1 therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Mereo BioPharma Group

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etigilimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : OrbiMed

                            Deal Size : $70.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Mereo BioPharma Announces Completion of $70 Million Private Placement and Plans to Develop Etigilimab

                            Details : Along with this private placement, Mereo plans to advance etigilimab (Anti-TIGIT) into a Phase 1b study alongside progressing its rare disease product portfolio, based on the Company’s existing promising clinical data with etigilimab.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 04, 2020

                            Lead Product(s) : Etigilimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : OrbiMed

                            Deal Size : $70.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth